This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.Here is a sample of this item:ZIOPHARM Presents Positive Palifosfamide Sarcoma Randomized Phase II Interim Data at Annual Meeting of the Connective Tissue Oncology Society 2009-11-06 07:13 ET - News Release -- Palifosfamide prolongs progression-free survival by at least 50% -- 
Company Website:
http://www.ziopharm.com
NEW YORK -- (Business Wire)
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) presented today at the 15th
Annual Connective Tissue Oncology Society (CTOS) Meeting, positive
interim data from the multicenter randomized Phase II trial of
palifosfamide (ZymafosTM, ZIO-201) treating patients with
unresectable or metastatic soft tissue sarcoma. As previously announced,
having achieved the study-specified efficacy milestone following planned
safety and efficacy review by the Data Committee, a panel of
international sarcoma experts, and the Company’s Medical Advisory Board,
it was determined that the data are compelling and sufficient to proceed
to a pivotal study in support of product registration and to conclude
enrollment in the trial.
The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try,
click here for a free 30 day trial subscription. |
Top
Print this Page